A CAR T-cell therapy targeting B-cells, a type of immune cells, was found to clear disease-causing autoantibodies from the bloodstream of eight people with systemic lupus erythematosus (SLE) — without compromising the patients’ ability to respond to vaccines — new trial data show. The experimental therapy also drove the…
Kyverna Therapeutics has signed a research funding deal with Charité – Universitätsmedizin Berlin, in Germany, to study how therapies targeting immune B-cells may improve clinical outcomes of people with whole-body, or systemic, autoimmune diseases such as lupus. The deal also covers studies on CAR T-cell therapies, including Kyverna’s experimental…
Depression and anxiety are more likely in people with systemic lupus erythematosus (SLE) who also are at a greater risk of heart disease, like those with obesity or high blood pressure, a study reports. “The findings of this study suggest the need for more intensive and global care, particularly…
This year’s winners of the Lupus Foundation of America‘s Gary S. Gilkeson Career Development Award — designed to support early career scientists working on lupus research — will focus their work on areas key to patients with the autoimmune disease: pregnancy and personalized medicine. Both winners are from…
A team of scientists in Austria discovered a small molecule — now called feeblin in a nod to a Nobel laureate— that prevents the activation of immune signaling pathways implicated in systemic lupus erythematosus (SLE). This molecule was found to block the interaction of two key proteins, known as…
Lupus Therapeutics is partnering with AbbVie for the Phase 3 clinical program of upadacitinib for people with systemic lupus erythematosus (SLE). “The partnership with AbbVie will support the accelerated evaluation of upadacitinib as a potential treatment for individuals living with SLE,” Stacie Bell, PhD, Lupus Therapeutics’…
Lupus Therapeutics will partner with Nkarta to advance the development of NKX019, Nkarta’s investigational natural killer (NK) cell therapy, for people with treatment-resistant lupus nephritis, a serious complication of lupus that features kidney damage and dysfunction. The U.S. Food and Drug Administration (FDA) recently cleared the launch…
The U.S. Food and Drug Administration (FDA) has approved Nkarta’s request to launch a clinical trial in the U.S. to test its experimental therapy NKX019 in people with lupus nephritis, a lupus complication marked by kidney inflammation and damage. The multi-center, dose-escalation study will assess the safety and clinical…
Treatment with an intensified dosing regimen of Saphnelo (anifrolumab) led to greater improvements in kidney function compared with standard dosing or a placebo for people with active lupus nephritis, according to two-year data from the TULIP-LN clinical trial. Lupus nephritis is a common, yet severe manifestation of lupus…
The U.S. Food and Drug Administration (FDA) has granted fast track designation to IMPT-514, a CAR T-cell therapy being developed by Immpact Bio for people with active, treatment-resistant lupus nephritis and systemic lupus erythematosus (SLE). Lupus nephritis is a serious complication of lupus characterized by kidney inflammation.